Cardiology 2013. Part II.
March 9, 2014
ISSN: 1579-2242 (Electronic)
Accession Number: 23352558
Abstract: This article summarizes the main developments reported during the year 2012 concerning ischemic heart disease, together with the most relevant innovations in the management of acute cardiac patients. Full English text available from:www.revespcardiol.org/en.
Notes: Jimenez-Candil, Javier
Barrabes, Jose A
Garcia de la Villa, Bernardo
Bodi Peris, Vicente
Lopez Palop, Ramon
Rev Esp Cardiol. 2013 Mar;66(3):198-204. doi: 10.1016/j.recesp.2012.10.019. Epub 2013 Jan 23.
Author Address: Servicio de Cardiologia, IBSAL-Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Espana. Electronic address: firstname.lastname@example.org.
Reference Type: Journal Article
Record Number: 868Author: Jones, D. A., Choudry, F. and Mathur, A.
Title: Almanac 2012: cell therapy in cardiovascular disease. the national society journals present selected research that has driven recent advances in clinical cardiology
Journal: Hellenic J Cardiol
Short Title: Almanac 2012: cell therapy in cardiovascular disease. the national society journals present selected research that has driven recent advances in clinical cardiology
Alternate Journal: Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
ISSN: 2241-5955 (Electronic)
Accession Number: 23685652
Keywords: Almanacs as Topic
Cell- and Tissue-Based Therapy/*methods
Abstract: The rapid translation from bench to bedside that has been seen in the application of regenerative medicine to cardiology has led to exciting new advances in our understanding of some of the fundamental mechanisms related to human biology. The first generation of cells used in phase l-ll trials (mainly bone marrow mononuclear cells) are now entering phase III clinical trials with the goal of producing a cell-based therapeutic that can change the outcome of cardiac disease. First generation cell therapy appears to have addressed safety concerns as well as showing “activity” in numerous published meta-analyses. With the knowledge gained to date, the field is moving towards the next generation of cells-the “engineered” cell-that have been developed to display a phenotype that will further enhance the myocardial repair/salvage process. This almanac review covers the latest basic research that may soon have application to humans as well as the results of the latest clinical trials.